PMID- 35529867
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220716
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 
      Convalescent Patients.
PG  - 869990
LID - 10.3389/fimmu.2022.869990 [doi]
LID - 869990
AB  - The emergence of novel variants of the severe acute respiratory syndrome 
      coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from 
      spreading despite available vaccines. Reports of breakthrough infections and 
      decreased capacity of antibodies to neutralize variants raise the question 
      whether current vaccines can still protect against COVID-19 disease. We studied 
      the dynamics and persistence of T cell responses using activation induced marker 
      (AIM) assay and Th1 type cytokine production in peripheral blood mononuclear 
      cells obtained from BNT162b2 COVID-19 mRNA vaccinated health care workers and 
      COVID-19 patients. We demonstrate that equally high T cell responses following 
      vaccination and infection persist at least for 6 months against Alpha, Beta, 
      Gamma, and Delta variants despite the decline in antibody levels.
CI  - Copyright (c) 2022 Hurme, Jalkanen, Heroum, Liedes, Vara, Melin, Terasjarvi, He, 
      Poysti, Hanninen, Oksi, Vuorinen, Kantele, Tahtinen, Ivaska, Kakkola, Lempainen 
      and Julkunen.
FAU - Hurme, Antti
AU  - Hurme A
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
AD  - Department of Infectious Diseases, Turku University Hospital and University of 
      Turku, Turku, Finland.
FAU - Jalkanen, Pinja
AU  - Jalkanen P
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
FAU - Heroum, Jemna
AU  - Heroum J
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
FAU - Liedes, Oona
AU  - Liedes O
AD  - Department of Health Security, Finnish Institute for Health and Welfare, 
      Helsinki, Finland.
FAU - Vara, Saimi
AU  - Vara S
AD  - Department of Health Security, Finnish Institute for Health and Welfare, 
      Helsinki, Finland.
FAU - Melin, Merit
AU  - Melin M
AD  - Department of Health Security, Finnish Institute for Health and Welfare, 
      Helsinki, Finland.
FAU - Terasjarvi, Johanna
AU  - Terasjarvi J
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
FAU - He, Qiushui
AU  - He Q
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
FAU - Poysti, Sakari
AU  - Poysti S
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
AD  - Clinical Microbiology, Turku University Hospital, Turku, Finland.
FAU - Hanninen, Arno
AU  - Hanninen A
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
AD  - Clinical Microbiology, Turku University Hospital, Turku, Finland.
FAU - Oksi, Jarmo
AU  - Oksi J
AD  - Department of Infectious Diseases, Turku University Hospital and University of 
      Turku, Turku, Finland.
FAU - Vuorinen, Tytti
AU  - Vuorinen T
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
AD  - Clinical Microbiology, Turku University Hospital, Turku, Finland.
FAU - Kantele, Anu
AU  - Kantele A
AD  - Meilahti Vaccine Research Center, MeVac, Department of Infectious Diseases, 
      Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
FAU - Tahtinen, Paula A
AU  - Tahtinen PA
AD  - Department of Paediatrics and Adolescent Medicine, Turku University Hospital and 
      University of Turku, Turku, Finland.
FAU - Ivaska, Lauri
AU  - Ivaska L
AD  - Department of Paediatrics and Adolescent Medicine, Turku University Hospital and 
      University of Turku, Turku, Finland.
FAU - Kakkola, Laura
AU  - Kakkola L
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
FAU - Lempainen, Johanna
AU  - Lempainen J
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
AD  - Department of Paediatrics and Adolescent Medicine, Turku University Hospital and 
      University of Turku, Turku, Finland.
FAU - Julkunen, Ilkka
AU  - Julkunen I
AD  - Institute of Biomedicine, University of Turku, Turku, Finland.
AD  - Clinical Microbiology, Turku University Hospital, Turku, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220422
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Viral)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - N38TVC63NU (BNT162 Vaccine)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - Antibodies, Viral
MH  - BNT162 Vaccine
MH  - *COVID-19
MH  - COVID-19 Vaccines
MH  - Humans
MH  - Leukocytes, Mononuclear
MH  - RNA, Messenger/genetics
MH  - *SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus
MH  - T-Lymphocytes
PMC - PMC9073085
OTO - NOTNLM
OT  - BNT162b2
OT  - Covid-19
OT  - T cell mediated immunity
OT  - humoral immunity
OT  - vaccine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/10 06:00
MHDA- 2022/05/11 06:00
PMCR- 2022/04/22
CRDT- 2022/05/09 04:16
PHST- 2022/02/05 00:00 [received]
PHST- 2022/03/29 00:00 [accepted]
PHST- 2022/05/09 04:16 [entrez]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2022/04/22 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.869990 [doi]
PST - epublish
SO  - Front Immunol. 2022 Apr 22;13:869990. doi: 10.3389/fimmu.2022.869990. eCollection 
      2022.